arrow
S

Stephen P. Mulligan

the university of sydney
H指数:37
被引数:8,311

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

慢性淋巴细胞白血病初始免疫化疗后的来那度胺维持治疗——ALLG和FILO国际III期CLL6研究RESIDUUM部分的最终分析

2026-09-210
OAAI
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

固定疗程维奈克拉 vs FCR/BR 在初治慢性淋巴细胞白血病患者中的疗效:CRISTALLO III期试验主要分析

Blood
IF23.1
2026-03-040
OA
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

CRISTALLO:一项关于Venetoclax-Obinutuzumab与Fludarabine、Cyclophosphamide和Rituximab或Bendamustine-Rituximab治疗无Del(17p)或TP53突变初治慢性淋巴细胞白血病患者Ⅲ期试验的结果

BLOOD
IF23.1
2024-11-050
PRE
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
2024-03-283
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

BTK和PLCG2在接受依鲁替尼治疗的CLL复发患者的3分之1中保持未突变

2023-06-1638
OAAI
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
LEUKEMIA
IF13.4
2021-06-2454
OAAI
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial
2020-12-0763
OAAI
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
2020-05-13100
OAAI
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
2019-10-13353
OAAI